Earnings Alerts

Mckesson Corp (MCK) Earnings: First Quarter Results Exceed Expectations and Boost FY Adjusted EPS Forecast

  • Increase in Forecast: McKesson raised its full-year adjusted EPS forecast to $31.75-$32.55 from $31.25-$32.05.
  • First Quarter Adjusted EPS: The company reported adjusted EPS of $7.88, up from $7.27 year-over-year and above the estimated $7.17.
  • Revenue Figures:
    • Total revenue for the first quarter was $79.28 billion, up 6.4% year-over-year, though it missed the $82.65 billion estimate.
    • US pharmaceutical revenue rose 6.8% year-over-year to $71.72 billion, below the estimate of $75.78 billion.
    • International revenue was $3.69 billion, a 6.4% increase year-over-year, slightly above the $3.67 billion estimate.
    • Medical-surgical solutions revenue increased by 1% year-over-year to $2.64 billion, falling short of the $2.77 billion estimate.
    • Prescription technology solutions revenue was $1.24 billion, down 0.2% year-over-year and below the $1.46 billion estimate.
  • Analyst Ratings: Out of the analysts covering McKesson, 15 recommend buying, 3 suggest holding, and 1 advises selling.

Mckesson Corp on Smartkarma

Analysts on Smartkarma, like Baptista Research, have provided positive coverage on Mckesson Corp, a diversified healthcare services company. In their research report titled “McKesson Corporation: How Is The Revenue and Profit Growth Across Segments Expected To Evolve? – Major Drivers,” they highlight the company’s strong financial performance in the Fourth Quarter Fiscal 2024. Mckesson reported a consolidated revenue increase of 12% to $309 billion, surpassing initial expectations. The analysts commend Mckesson’s growth achieved through its portfolio of assets, innovative solutions, and operational excellence.

Furthermore, Baptista Research‘s report “McKesson Corporation: Anticipated Revenue Growth in Medical-Surgical Solutions Could Propel Them Forward! – Major Drivers” emphasizes Mckesson’s robust fiscal third-quarter earnings. With total revenues of $80.9 billion and adjusted earnings per share of $7.74, Mckesson demonstrated double-digit growth year over year. The analysts attribute this strong performance to the company’s focused execution of its long-term priorities, indicating a positive outlook for Mckesson Corp.


A look at Mckesson Corp Smart Scores

FactorScoreMagnitude
Value0
Dividend2
Growth5
Resilience5
Momentum5
OVERALL SMART SCORE3.4

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

McKesson Corp’s long-term outlook appears promising, as indicated by its high Smart Scores across various factors. With top scores in Growth, Resilience, and Momentum, the company seems poised for future success. Its strong focus on expanding operations and maintaining consistent performance suggests a positive trajectory ahead.

McKesson Corp, a company distributing pharmaceuticals and healthcare products in North America, demonstrates robust fundamentals with its high Smart Scores in key areas. Investors may find confidence in the company’s resilience, growth prospects, and positive momentum, indicating a potentially bright future for McKesson Corp.


Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.


 

πŸ’‘ Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • βœ“ Unlimited Research Summaries
  • βœ“ Personalised Alerts
  • βœ“ Custom Watchlists
  • βœ“ Company Analytics and News
  • βœ“ Events & Webinars